CN102072960A - Method for detecting neutrophil gelatinase-associated lipocalin (NGAL) in sample - Google Patents

Method for detecting neutrophil gelatinase-associated lipocalin (NGAL) in sample Download PDF

Info

Publication number
CN102072960A
CN102072960A CN 201010136227 CN201010136227A CN102072960A CN 102072960 A CN102072960 A CN 102072960A CN 201010136227 CN201010136227 CN 201010136227 CN 201010136227 A CN201010136227 A CN 201010136227A CN 102072960 A CN102072960 A CN 102072960A
Authority
CN
China
Prior art keywords
ngal
sample
antibody
people
elisa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN 201010136227
Other languages
Chinese (zh)
Inventor
华权高
沈鹤霄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WUHAN LIFE ORIGIN BIOTECH CO Ltd
Original Assignee
WUHAN LIFE ORIGIN BIOTECH CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WUHAN LIFE ORIGIN BIOTECH CO Ltd filed Critical WUHAN LIFE ORIGIN BIOTECH CO Ltd
Priority to CN 201010136227 priority Critical patent/CN102072960A/en
Publication of CN102072960A publication Critical patent/CN102072960A/en
Pending legal-status Critical Current

Links

Images

Abstract

The invention relates to a method for detecting neutrophil gelatinase-associated lipocalin (NGAL) in a sample. The method comprises the following steps of: reacting an antibody of the NGAL with human NGAL of a specimen to be detected to form a compound which causes turbidity change; characterizing the change by using light projection intensity or light scattering intensity; and finding out the content of the human NGAL in the specimen to be detected from the concentration of the NGAL standard product and a standard curve of corresponding light scattering intensity or light transmission intensity. The method has the advantages of high sensitivity, high recovery rate and good repeatability, and a detection measure having the advantages of simplicity, convenience, good repeatability, strong adaptability and high speed is determined for measuring the NGAL in the samples of urine or blood plasma, and the like.

Description

The detection method of neutrophil gelatinase-associated lipocalin in a kind of sample
Technical field
The present invention relates to the detection method of neutrophil gelatinase-associated lipocalin in a kind of sample.
Background technology
Neutrophil gelatinase-associated lipocalin (be called for short NGAL) be 1993 at first found in neutrophil leucocyte, relevant with processes such as the generation of inflammation, embryonic development, immune response, chemotaxis, signal transduction and kinds of tumors and development.Domestic and international research shows in recent years, and NGAL albumen is sent out the characteristics that have specific expressed variation in the process in multiple disease, makes NGAL become the biomarker that detects disease.
In ischemic and toxicity injury of kidney process take place, the NGAL in the renal cells will significantly increase, and in two hours of beginning, the NGAL level will significantly increase in urine and the blood, so NGAL is the responsive mark of early stage acute injury of kidney.
Acute renal damage prognosis will develop into acute renal failure.General diagnostic method is as measuring serum creatinine or cysteine proteinase inhibitor C (Cystatin C), can only damage one day after very the person detect in several days.There are some researches show, NGAL content detection distribution of results 0.7-9.6ng/ml in healthy volunteer's urine, mean value is 5.3ng/ml.And the content detection result in the blood plasma is 37-106ng/ml, and mean value is 63ng/ml.Behind injury of kidney, with the machine testing severe case, the concentration of urine NGAL is that 110ng/ml does not wait to 40000ng/ml.And their EDTA anticoagulate plasma testing result is that 25ng/ml is to 3491ng/ml.Judge that according to 90% positive predictive value that the acute renal failure patient detects the positive judgment value of NGAL is 350ng/ml in the urine, and the positive judgment value that blood plasma detects is 400ng/ml.
Homology analysis shows, (neu-related lipocalin NRL) has very high homology for NGAL and the 24p3 of mouse and the relevant lipocalin of neu of rat.The 24p3 of mouse is synthetic in liver, raises during inflammatory reaction, and 24p3 also sees macrophage and endometrium in addition, especially the endometrium in reproduction period.With steroid hormone the 24p3 level in the respective organization is raise, and some growth factors and tumour promote that the factor also can make its rising.Monkey poison SV40, polyoma poison or other malicious infection can stimulate the expression of the mouse kidney cell 24p3mRNA of cultivation to increase 7-10 doubly.And raise along with the synthetic increase of large T antigen.Therefore 24p3 is considered to oncoprotein.This shows that simultaneously NGAL may be human a kind of new oncogene.
The expression that experiment showed, the NGAL in ovarian cancer cell line, colon tumor and breast cancer etc. obviously strengthens.The NGAL strong positive of SABC proof in cancerous lung tissue, and BAC cancer and carcinoma muco-cellulare dyeing are the strongest, NGAL can be increased to strong positive from feminine gender in cancer of pancreas.
In sum, set up at the method for quick of NGAL in the sample and will provide a strong tool for the research of this albumen.
Summary of the invention
The invention provides the described method of method that detects NGAL in the sample and comprise following steps:
I) use related equipment to collect serum, blood plasma and urine that sample comprises the people,
Ii) sample and antibody contact reaction,
Iii) detect the concentration of NGAL in the sample.
Preferably measure the NGAL level by immuno-chemical method, the example of this method comprises but never is limited to immunoturbidimetry, sandwich method ELISA, competition law ELISA.
To biological specimen, can carry out with any method of satisfied analysis specificity, sensitivity and degree of accuracy that provides.In the test experience, use monoclonal, polyclonal antibody or any molecule that can combine of NGAL with the NGAL specificity.The binding molecule at first NGAL that catches in the sample of immobilization forms compound, and the detectable binding molecule of another one mark is again in conjunction with above-mentioned compound, thereby the value indirect reaction that demonstrates the compound amount by ad hoc approach at last goes out the content of NGAL in the sample.Can directly utilize antibody that free NGAL antibody or coupling latex particle exist with colloidal form and NGAL in the sample directly to combine formed compound in addition and cause that turbidity changes; Use up projection intensity or light scattering intensity and characterize this variation; Find the content of the people NGAL of sample to be checked from the typical curve of the concentration of people NGAL standard items and corresponding light scattering strength or transmittance intensity;
Description of drawings
Fig. 1 is that sandwich method ELISA detects recombined human NGAL canonical plotting;
Fig. 2 is that competition law ELISA detects recombined human NGAL canonical plotting.
Embodiment
Following examples are used to illustrate the present invention, but are not used for limiting the scope of the invention.
Embodiment 1 latex enhance immunity turbidimetry detects the NGAL content in the human urine
Realize the technical scheme of this example: the immunoturbidimetry of a kind of people of detection NGAL, at first crosslinked with latex with the polyclonal antibody of anti-NGAL, with the NGAL reaction of latex solution after crosslinked and sample to be checked, formed compound causes that turbidity changes then; Use up projection intensity or light scattering intensity and characterize this variation; Find the NGAL content of sample to be checked from the typical curve of the concentration of NGAL standard items and corresponding light scattering strength or light projection intensity; The polyclonal antibody of wherein used NGAL is tired and is at least 1: 500, does not contain assorted antibody, has many kinds of antigenic determinants of identification NGAL; Sample to be checked does 1 with thinning agent: 200-1: 1000 dilutions;
In the said method, described NGAL standard items are pure NGAL, and its concentration is 0.2mg/ml, do 1: 200 times of dilution with thinning agent earlier, do doubling dilution again, make the series standard product, are made for typical curve and use;
Embodiment 2 usefulness sandwich method ELISAs are determined human urine NGAL concentration
Concrete steps are: bag is by the NGAL antibody A; Prepare serial NGAL standard items; Prepare human urine; The human urine of series standard product or required value is added in the 96 micropore plate holes, make again mark, binding site is different from the antibody B combination that is coated on antibody A on 96 microwell plates, with matrix liquid colour developing color development stopping after 20-30 minute, measure the reacted absorbance of NGAL in above-mentioned series standard product and the human urine to be detected after 10 minutes; Set up the typical curve of the concentration of series standard product and absorbance and from curve, find the concentration of NGAL of the human urine of required value.
Embodiment 3 usefulness competition law ELISA determine human urine NGAL concentration
Concrete steps are: bag is by the NGAL polyclonal antibody; Prepare serial NGAL standard items; Prepare human urine; Make the human urine of series standard product or required value and the NGAL standard items mixing of mark; With matrix liquid colour developing color development stopping after 20-30 minute, measure the reacted absorbance of NGAL in above-mentioned series standard product and the human urine to be detected after 10 minutes; Set up the typical curve of the concentration of series standard product and absorbance and from curve, find the concentration of NGAL of the human urine of required value.

Claims (12)

1. the detection method of neutrophil gelatinase-associated lipocalin in the sample.
2. method according to claim 1, it is characterized in that, be based upon on the antigen and antibody specific reaction principle basis, by the concentration of the relevant lipocalin protein (NGAL) of human neutrophil gelatinase in the immunological method test sample that includes but not limited to immunoturbidimetry and enzyme linked immunological (ELISA) method.
3. method according to claim 1 is characterized in that, comprises the steps:
I) use related equipment to collect sample and comprise serum, blood plasma and urine,
Ii) NGAL in the sample and antibody contact reaction,
Iii) detect the concentration of people NGAL in the sample.
4. sample according to claim 2 is characterized in that including but not limited to people's urine, blood plasma and serum.
5. antibody according to claim 3 is characterized in that this antibody is polyclonal antibody or the monoclonal antibody by the people NGAL immune animal acquisition of natural or reorganization.
6. immunoturbidimetry according to claim 2 is characterized in that: with the antibody of anti-people NGAL, with the people NGAL reaction of sample to be checked, formed compound causes that turbidity changes; Use up projection intensity or light scattering intensity and characterize this variation; Find the content of the people NGAL of sample to be checked from the typical curve of the concentration of people NGAL standard items and corresponding light scattering strength or transmittance intensity.
7. enzyme linked immunological according to claim 2 (ELISA) method is characterized in that: comprise double antibodies sandwich method ELISA, competition law ELISA.
8. enzyme linked immunological according to claim 2 (ELISA) method, it is characterized in that: people NGAL is immobilization in advance, or people NGAL antibody immobilization in advance.
9. enzyme linked immunological according to claim 2 (ELISA) method is characterized in that: the scope that detects NGAL content is: 7.8ng/ml-500ng/ml.
10. competition law according to claim 7 is if direct competition method is characterized in that: immobilization people NGAL antibody in advance.
11. competition law according to claim 7 is if the indirect competition method is characterized in that: immobilization people NGAL in advance.
12. immobilization according to claim 8, it is characterized in that: with people NGAL or people NGAL antibody sandwich to solid support, this holder can be, the polystyrene or the polyvinyl chloride surface that for example are used for enzyme linked immunosorbent assay, or latex (polystyrene) particle, or by the filter glass rod formed of polyethylene particle of compression, or porous digest cellulose matrix, or in fact be any suitable holder in the immunochemical analyses use.
CN 201010136227 2010-03-29 2010-03-29 Method for detecting neutrophil gelatinase-associated lipocalin (NGAL) in sample Pending CN102072960A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 201010136227 CN102072960A (en) 2010-03-29 2010-03-29 Method for detecting neutrophil gelatinase-associated lipocalin (NGAL) in sample

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 201010136227 CN102072960A (en) 2010-03-29 2010-03-29 Method for detecting neutrophil gelatinase-associated lipocalin (NGAL) in sample

Publications (1)

Publication Number Publication Date
CN102072960A true CN102072960A (en) 2011-05-25

Family

ID=44031580

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 201010136227 Pending CN102072960A (en) 2010-03-29 2010-03-29 Method for detecting neutrophil gelatinase-associated lipocalin (NGAL) in sample

Country Status (1)

Country Link
CN (1) CN102072960A (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102662064A (en) * 2012-04-26 2012-09-12 苏州照康生物技术有限公司 Immunonephelometry kit for detecting lipid carrier protein related to neutrophils gelatinase and preparation method thereof
CN102680698A (en) * 2011-07-29 2012-09-19 南京诺尔曼生物技术有限公司 Neutrophil gelatinase-associated lipocalin (NGAL) assay kit (latex-enhanced immunoturbidimetry)
CN102775473A (en) * 2012-07-30 2012-11-14 重庆业为基生物科技有限公司 B cell epitope peptide of human neutrophil gelatinase associated lipocalin and application thereof
CN102967714A (en) * 2012-12-10 2013-03-13 天津市协和医药科技集团有限公司 Neutrophil gelatinase associated lipocalin (NGAL) chemiluminescence detection kit
CN103048464A (en) * 2012-10-17 2013-04-17 武汉生之源生物科技有限公司 Neutrophile granulocyte gelatinase related lipid transport protein detection kit and preparation method thereof
WO2013097606A1 (en) * 2011-12-30 2013-07-04 北京九强生物技术股份有限公司 Assay kit for neutrophil gelatinase-associated lipocalin
CN104198732A (en) * 2014-08-28 2014-12-10 宁波瑞源生物科技有限公司 Kit for detecting content of neutrophil gelatinase-associated lipocalin (NGAL)
CN104313157A (en) * 2014-10-27 2015-01-28 东南大学 Method for detecting NGAL with proximity ligation technology
WO2018076284A1 (en) * 2016-10-28 2018-05-03 The University Of Hong Kong Non-polyaminated lcn2 as a biomarker for diagnosis and treatment of cardiometabolic diseases

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1791797A (en) * 2003-03-27 2006-06-21 儿童医院医疗中心 A method and kit for detecting the early onset of renal tubular cell injury
CN101027556A (en) * 2004-06-07 2007-08-29 儿童医院医疗中心 Method for the early detection of renal disease and injury
CN101163971A (en) * 2004-12-20 2008-04-16 免疫体公司 Determination of neutrophil gelatinase-associated lipocalin (ngal) as a diagnostic marker for renal disorders
WO2008061149A2 (en) * 2006-11-14 2008-05-22 Biosite Incorporated Methods and compositions for diagnosis and prognosis of renal artery stenosis
CN101421622A (en) * 2006-02-17 2009-04-29 儿童医学中心公司 Free NGAL as a biomarker for cancer
CN101566633A (en) * 2009-04-17 2009-10-28 武汉华美生物工程有限公司 Method for diagnosing, evaluating or testing cancer and foreseeing cancer severity

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1791797A (en) * 2003-03-27 2006-06-21 儿童医院医疗中心 A method and kit for detecting the early onset of renal tubular cell injury
CN101027556A (en) * 2004-06-07 2007-08-29 儿童医院医疗中心 Method for the early detection of renal disease and injury
CN101163971A (en) * 2004-12-20 2008-04-16 免疫体公司 Determination of neutrophil gelatinase-associated lipocalin (ngal) as a diagnostic marker for renal disorders
CN101421622A (en) * 2006-02-17 2009-04-29 儿童医学中心公司 Free NGAL as a biomarker for cancer
WO2008061149A2 (en) * 2006-11-14 2008-05-22 Biosite Incorporated Methods and compositions for diagnosis and prognosis of renal artery stenosis
CN101566633A (en) * 2009-04-17 2009-10-28 武汉华美生物工程有限公司 Method for diagnosing, evaluating or testing cancer and foreseeing cancer severity

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102680698B (en) * 2011-07-29 2016-03-30 南京诺尔曼生物技术有限公司 Neutrophil gelatinase-associated lipocalin (NGAL) measures kit (latex enhancing immune turbidimetry)
CN102680698A (en) * 2011-07-29 2012-09-19 南京诺尔曼生物技术有限公司 Neutrophil gelatinase-associated lipocalin (NGAL) assay kit (latex-enhanced immunoturbidimetry)
WO2013097606A1 (en) * 2011-12-30 2013-07-04 北京九强生物技术股份有限公司 Assay kit for neutrophil gelatinase-associated lipocalin
CN102662064A (en) * 2012-04-26 2012-09-12 苏州照康生物技术有限公司 Immunonephelometry kit for detecting lipid carrier protein related to neutrophils gelatinase and preparation method thereof
CN102775473A (en) * 2012-07-30 2012-11-14 重庆业为基生物科技有限公司 B cell epitope peptide of human neutrophil gelatinase associated lipocalin and application thereof
CN102775473B (en) * 2012-07-30 2018-10-12 重庆业为基生物科技有限公司 The B cell epitope peptide fragment of human neutrophil gelatinase-associated lipocalin and its application
CN103048464A (en) * 2012-10-17 2013-04-17 武汉生之源生物科技有限公司 Neutrophile granulocyte gelatinase related lipid transport protein detection kit and preparation method thereof
CN103048464B (en) * 2012-10-17 2015-04-15 武汉生之源生物科技有限公司 Neutrophile granulocyte gelatinase related lipid transport protein detection kit and preparation method thereof
CN102967714A (en) * 2012-12-10 2013-03-13 天津市协和医药科技集团有限公司 Neutrophil gelatinase associated lipocalin (NGAL) chemiluminescence detection kit
CN104198732A (en) * 2014-08-28 2014-12-10 宁波瑞源生物科技有限公司 Kit for detecting content of neutrophil gelatinase-associated lipocalin (NGAL)
CN104198732B (en) * 2014-08-28 2015-08-19 宁波瑞源生物科技有限公司 A kind of neutrophil gelatinase-associated lipocalin reagent box for detecting content
CN104313157A (en) * 2014-10-27 2015-01-28 东南大学 Method for detecting NGAL with proximity ligation technology
WO2018076284A1 (en) * 2016-10-28 2018-05-03 The University Of Hong Kong Non-polyaminated lcn2 as a biomarker for diagnosis and treatment of cardiometabolic diseases

Similar Documents

Publication Publication Date Title
CN102072960A (en) Method for detecting neutrophil gelatinase-associated lipocalin (NGAL) in sample
WO2017107974A1 (en) Detection test kit for serum psmd4 proteins and detection method and application thereof
JP6096813B2 (en) Multi-biomarker set for breast cancer diagnosis, detection method thereof, and breast cancer diagnosis kit including antibody thereto
CN101566633A (en) Method for diagnosing, evaluating or testing cancer and foreseeing cancer severity
CN104374919A (en) Method for measurement of glycoprotein, reagent and sugar chain marker
CN101377492A (en) Bladder chalone C determining reagent kit
CN102507918B (en) Kit for determining anti-cyclic citrullinated peptide (Anti-CCP) antibody
CN105572353B (en) A kind of antibody chip kit for detecting liver cancer marker
Liu et al. Methodological evaluation and comparison of five urinary albumin measurements
US7081347B2 (en) Method for predicting cardiovascular events
CN114200132B (en) Kit for detecting thyroglobulin antibody and subtype thereof
US20120252040A1 (en) Kit for diagnosing prostate cancer and diagnosis method
Chin et al. Dual-enhanced plasmonic biosensing for point-of-care sepsis detection
Lund et al. Exploring the complementary selectivity of immunocapture and MS detection for the differentiation between hCG isoforms in clinically relevant samples
CN112166323A (en) Direct immunoassay measurement of autoantibodies
CN108463724B (en) Method for determining cancer, device for determining cancer, and computer program
KR102172016B1 (en) A method for detection of CYFRA21-1 Autoantibody-Antigen complex , CYFRA21-1 antigen and Lung Cancer diagnosis kit by using ratio of these markers
JP2010091308A (en) Method for diagnosing prostate carcinoma by lectin absorbing method and prostate carcinoma determining kit
CN206638678U (en) Multi objective time-resolved fluoroimmunoassay for postoperative patient monitoring chromatographs kit
JP2019053068A (en) Sensitive multiplex immunoassay for soluble fibroblast growth factor receptors
CN108802400B (en) Method for detecting compound IgA 1-alpha 1MG and kit for non-invasive detection of renal tissue injury
AU781669B2 (en) Detection of prostate cancer measuring PSA/IGF-1 ratio
EP3879270A1 (en) Method for detecting viral liver cancer
US11242408B2 (en) Monoclonal antibody specific for gamma-glutamyl-l-epsilon-lysine for the monitoring of apoptosis
KR101547058B1 (en) Microsphere bead and Method for determination of protein using microsphere bead

Legal Events

Date Code Title Description
DD01 Delivery of document by public notice

Addressee: Wuhan Life Origin Biotech Co., Ltd.

Document name: Notification of Passing Preliminary Examination of the Application for Invention

C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20110525